KR860008181A - 7-치환된 바이시클릭 피라졸리디논의 제조방법 - Google Patents
7-치환된 바이시클릭 피라졸리디논의 제조방법 Download PDFInfo
- Publication number
- KR860008181A KR860008181A KR1019860003251A KR860003251A KR860008181A KR 860008181 A KR860008181 A KR 860008181A KR 1019860003251 A KR1019860003251 A KR 1019860003251A KR 860003251 A KR860003251 A KR 860003251A KR 860008181 A KR860008181 A KR 860008181A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- substituted
- alkyl
- group
- arylalkyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- NDGRWYRVNANFNB-UHFFFAOYSA-N pyrazolidin-3-one Chemical compound O=C1CCNN1 NDGRWYRVNANFNB-UHFFFAOYSA-N 0.000 title abstract 2
- 125000002619 bicyclic group Chemical class 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 37
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 27
- 239000001257 hydrogen Substances 0.000 claims abstract 27
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 27
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 150000002431 hydrogen Chemical group 0.000 claims abstract 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 10
- 125000002252 acyl group Chemical group 0.000 claims abstract 8
- -1 bicyclic pyrazolidinone compound Chemical class 0.000 claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 8
- 150000001767 cationic compounds Chemical class 0.000 claims abstract 7
- 229910001411 inorganic cation Inorganic materials 0.000 claims abstract 7
- 150000002892 organic cations Chemical class 0.000 claims abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 5
- 231100000252 nontoxic Toxicity 0.000 claims abstract 5
- 230000003000 nontoxic effect Effects 0.000 claims abstract 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract 4
- 150000002148 esters Chemical class 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 125000006239 protecting group Chemical group 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000001246 bromo group Chemical group Br* 0.000 claims abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 125000002346 iodo group Chemical group I* 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000005544 phthalimido group Chemical group 0.000 claims abstract 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims abstract 2
- 230000002503 metabolic effect Effects 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- STKARFFXWORTNB-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1CCN2C(=O)C=CN21 STKARFFXWORTNB-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 150000000475 acetylene derivatives Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 9
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- (A) 하기식(Ⅲ)의 일라이드를 하기식(Ⅳ)의 아세틸렌유도체와 반응시키거나; (B) 하기식(Ⅱ)의 화합물을 비-친핵성 염기로 처리하거나; (C) 하기식(Ⅴ)의 화합물을 염기성 조건하에 폐환시키거나; (D) 하기식(Ⅵ)의 화합물을 일반식 P(OR9)3의 화합물로 폐환시키거나; (E) R1또는 R2가 -COOR14이고 R9및/또는 R14가 카복시 보호그룹인 하기식(Ⅰ)의 화합물을 보호기 제거하거나; (F) R5및 R6가 수소인 하기식(Ⅰ)의 화합물을 아실화시켜, R5및 R6중 하나가 C1-C30카복실산으로부터 유도된 아실그룹인 화합물을 수득하고, 필요시 분자내의 모든 보호그룹을 제거하거나; (G) 하기식(Ⅶ)의 화합물을 염기의 존재하에 디페닐포스포릴 아지드와 반응시키고, 이어서 일반식 R8OH의 알콜과 반응시켜 하기 식(Ⅷ)의 우레아유도체를 수득하거나; (H) 하기식(Ⅸ)의 화합물을 가열분해하여 R2가 할로인 하기식(Ⅰ)의 화합물을 수득하거나; (Ⅰ) 하기식(Ⅹ)의 화합물을 제2구리 화합물로 처리하여 R2가 히드록시인 하기식(J)의 화합물을 수득하거나; (J) R2가 -OL이고 L이 수소 또는 이탈그룹인 하기식(Ⅰ)의 화합물을 알킬화제로 알킬화시켜 R2가 -OR11이고 R11이 수소가 아닌 하기식(Ⅰ)의 화합물을 수득하거나; (K) R2가 -OH인하기식(Ⅰ)의 화합물을 일반식 R12R13NH의 아민 또는 이의 염과 반응시킴을 특징으로 하는, 하기식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 제조방법.상기식에 있어서, R1및 R2중 하나는 수소, 할로, C1-C6알킬, C1-C6치환된 알킬, 퍼플루오로 C2-C4알킬, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐, 치환된 페닐, 헤테로시클릭 환, 니트로 또는 시아노; 일반식 -CX3[X는 플루오로, 클로로, 브로모 또는 요오도이다]의 그룹; 일반식[Z는 0.1 또는 2이고, R7은 C1-C6알킬, C1-치환된 알킬, 페닐, 치환된 페닐, C6-C7아릴알킬, C12-C7치환된 아릴알킬 도는 헤테로시클릭 환이다]의 그룹; 일반식 -COR8[R8은 수소, C1-C6알킬, C1-C6치환된 알킬, 퍼플루오로 C2-C4알킬, 트리할로메틸, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐, 치환된 페닐, 아미노, (모노 치환된) 아미노 또는 (디치환된)아미노이다]의 그룹; 일반식 -COOR9[R9는 수소, 유기 또는 무기 양이온, C1-C6알킬, C1-C6치환된 알킬, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐, 치환된 페닐, 카복시 부호그룹, 또는 무독성 대사성 에스테르형성 그룹이다]의 그룹; 일반식 -PO3(R10)2[R10은 수소, 유기 또는 무기양이온, C1-C6알킬, C1-C6치환된 알킬, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐 또는 치환된 페닐이다]의 그룹; 일반식는 4급 암모늄 그룹이다]의 그룹; 구조식 -CH2-S-헤테로시클릭환의 그룹; 일반식 -OR11[R11은 수소, C1-C6알킬, C1-C6치환된 알킬, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐, 치환된 페닐 또는 C1-C7아실이다]의 그룹; 또는 일반식 -NR12R13[R12및 R13은 동일 또는 상이하며, 수소, C1-C6알킬, C1-C6치환된 알킬, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐, 치환된 페닐, C1-C7아실 또는 일반식(Rq는 C1-C6알킬, C7-C12아릴알킬 또는 페닐이다)의 그룹이다]의 그룹이고; R1및 R2중 다른 하나는 일반식 -COOR14[R14는 수소, 유기또는 무기양이온, 카복시보호그룹, 또는 무독성 대사성 에스테르 형성 그룹이다]의 그룹이며; R3및 R4는 동일 또는 상이하며, 수소, C1-C6알킬, C1-C6치환된 알킬, C7-C12아릴알킬, C7-C12치환된 아릴알킬, 페닐,치환된 페닐, 또는 일반식 -COOR15[R15는 R9의 정의와 동일하다]의 그룹이고; R5및 R6는 각각 수소 아미노 보호그룹 또는 C1-C30카복실산으로부터 유도된 아실그룹[단, R5및 R6중 적어도 하나는 수소이다]이거나; R5와 R6는 함께 프탈이미도 그룹을 형성하며; Q1및 Q2중하나는 일반식 -SO2Y [Y는 C1-C6알킬, C1-C6치환된 알킬, 페닐, 치환된 페닐, C7-C12아릴알킬 또는 C7-C12치환된 아릴알킬이다]의 그룹이고, 다른 하나는 수소이며; R9는 C1-C6알킬 또는 페닐이다.
- 제1항에 있어서, R1또는 R2가 헤테로시클릭환; 일반식 -COR8[R8은 아미노, (모노 치환된) 아미노, (디치환된)아미노이다] 또는 일반식 OR11또는 -NR12R13의 그룹이 아닌 일반식(Ⅰ) 화합물의 제조방법.
- 제1 또는 2항에 있어서, R1이 COOR14[R14는 수소, 유기 또는 무기 양이온, 또는 무독성대사성 에스테르 형성 그룹이다]인 방법.
- 제1항에 있어서, R5가 수소이고, R6가 C1-C30카복실산으로 부터 유도된 아실 그룹인 방법.
- 제1항에 있어서, R3및 R4가 수소인 방법.
- 제1항에 있어서, R2가 시아노 또는 CH2-2-헤테로시클릭 환인 방법.
- 제1항에 있어서, 7-NR5R6그룹의 배위가 S인 방법.
- 제1항에 있어서, 2-(카복실산)-3-시아노-7-[2-(2-아미노티아졸-4-일)-2-(Z)-메톡시이미노아세트아미도]8-옥소-1.5-디아지바이시클로[3.3.0]옥타-2-엔의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72902185A | 1985-04-30 | 1985-04-30 | |
| US729,021 | 1985-04-30 | ||
| US729021 | 1985-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR860008181A true KR860008181A (ko) | 1986-11-12 |
| KR880001092B1 KR880001092B1 (ko) | 1988-06-23 |
Family
ID=24929253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019860003251A KR880001092B1 (ko) | 1985-04-30 | 1986-04-28 | 7-치환된 바이시클릭 피라졸리디논 및 그의 제조방법 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US4716232A (ko) |
| EP (1) | EP0202046B1 (ko) |
| JP (2) | JPH0759582B2 (ko) |
| KR (1) | KR880001092B1 (ko) |
| CN (1) | CN86103619A (ko) |
| AT (1) | ATE60605T1 (ko) |
| AU (1) | AU5675586A (ko) |
| CA (1) | CA1274832A (ko) |
| DE (1) | DE3677253D1 (ko) |
| DK (1) | DK193086A (ko) |
| ES (1) | ES8801833A1 (ko) |
| GR (1) | GR861118B (ko) |
| HU (1) | HUT40660A (ko) |
| IL (1) | IL78634A0 (ko) |
| PT (1) | PT82468B (ko) |
| ZA (2) | ZA863170B (ko) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK193086A (da) * | 1985-04-30 | 1987-01-20 | Lilly Co Eli | 7-substituerede bicycliske pyrazolidinoner, fremgangsmaade til fremstilling heraf og mellemprodukter til brug ved fremgangsmaaden |
| US4940718A (en) * | 1985-04-30 | 1990-07-10 | Eli Lilly And Company | 7-substituted bicyclic pyrazolidinones, pharmaceutical compositions and use |
| US4935536A (en) * | 1987-05-21 | 1990-06-19 | Millipore Corporation | Protecting groups for asparagine and glutamine in peptide synthesis |
| IL86095A0 (ko) * | 1987-09-30 | 1988-09-30 | Lilly Co Eli | |
| US5011938A (en) * | 1989-10-02 | 1991-04-30 | Eli Lilly And Company | 7-substituted bicyclic pyrazolidinones |
| US5430145A (en) * | 1990-10-18 | 1995-07-04 | Merrell Dow Pharmaceuticals Inc. | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| US5308841A (en) * | 1990-12-21 | 1994-05-03 | Merrell Dow Pharmaceuticals Inc. | Amino and nitro containing tricyclic compounds useful as inhibitors of ACE |
| EP0534363B1 (en) * | 1991-09-27 | 1997-07-09 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| US5455242A (en) * | 1991-09-27 | 1995-10-03 | Merrell Dow Pharmaceuticals Inc. | Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace |
| US5457196A (en) * | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| NZ246811A (en) * | 1992-02-14 | 1996-02-27 | Merrell Dow Pharma | N-[pyrido (and oxazino and thiazino) benzazepine] 1-benzyl-1-(heterocyclyl(alkyl)carbonylthio) acetamide derivatives and pharmaceutical compositions |
| JP3360079B2 (ja) * | 1992-05-15 | 2002-12-24 | メレルダウファーマスーティカルズ インコーポレイテッド | エンケファリナーゼ及びＡＣＥの阻害剤として有用な新規なメルカプトアセチルアミドピリダゾ［１，２］ピリダジン、ピラゾロ［１，２］ピリダジン、ピリダゾ［１，２‐ａ］［１，２］ジアゼピン、及びピラゾロ［１，２‐ａ］［１，２］ジアゼピン誘導体類 |
| US5420271A (en) * | 1992-08-24 | 1995-05-30 | Merrell Dow Pharmaceuticals, Inc. | 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase |
| US5470845A (en) * | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
| CA2107644A1 (en) * | 1992-10-28 | 1994-04-29 | David R. Magnin | .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd |
| DE69329701T2 (de) * | 1992-10-30 | 2001-05-10 | Merrell Pharma Inc | Mercaptoacetylamid substituiertes bizyclisches laktam zur verwendung als enkephalinase und ace-hemmer |
| AU687507B2 (en) * | 1994-02-14 | 1998-02-26 | Merrell Pharmaceuticals Inc. | Mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace |
| WO1995021854A1 (en) * | 1994-02-14 | 1995-08-17 | Merrell Pharmaceuticals Inc. | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace |
| CA2183314C (en) * | 1994-02-14 | 1999-08-31 | Gary A. Flynn | Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace |
| US5530013A (en) * | 1994-02-14 | 1996-06-25 | American Home Products Corporation | Venlafaxine in the inducement of cognition enhancement |
| KR100348949B1 (ko) * | 1994-02-14 | 2003-01-24 | 메렐 파마슈티칼스 인크. | 엔케팔리나제의억제제로서유용한신규의인단-2-머캅토아세틸아미드디술파이드유도체 |
| US5484783A (en) * | 1994-03-24 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives |
| JPH10503468A (ja) * | 1994-03-24 | 1998-03-31 | メリル・フアーマシユウテイカルズ・インコーポレイテツド | 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のメルカプトアセチルアミドジスルフィド誘導体 |
| ES2141923T3 (es) * | 1994-03-24 | 2000-04-01 | Merrell Pharma Inc | Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto. |
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| US5786448A (en) * | 1996-11-07 | 1998-07-28 | Trega Biosciences, Inc. | Combinatorial libraries of cyclic urea and cyclic thiourea derivatives and compounds therein |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| AR077688A1 (es) | 2009-08-04 | 2011-09-14 | Takeda Pharmaceutical | Compuestos heterociclicos, utiles en el tratamiento de cancer |
| CN106883236B (zh) * | 2017-03-17 | 2018-12-04 | 浙江大学 | 一种制备含硫的n，n-双环吡唑烷酮类衍生物的方法 |
| CN115286635B (zh) * | 2022-08-22 | 2023-10-24 | 河南师范大学 | 一种手性并环吡唑啉酮类化合物的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065224A (en) | 1955-06-24 | 1962-11-20 | Bayer Ag | Process for the production of addition products of organic isocyanates and organic carbodiimides |
| US2938892A (en) | 1958-10-10 | 1960-05-31 | Little Inc A | Amides and process of preparing same with a monocarbodhmide |
| AR206201A1 (es) | 1972-06-29 | 1976-07-07 | Ciba Geigy Ag | Procedimiento para la obtencion de compuestos de acido 7beta-amino-3-cefem-3-01-4-carboxilico0-substituidos |
| GB1415910A (en) * | 1973-03-21 | 1975-12-03 | Kyowa Hakko Kogyo Kk | Benzothiazoles |
| DD110868A1 (ko) * | 1974-04-03 | 1975-01-12 | ||
| GB1472052A (en) * | 1975-02-14 | 1977-04-27 | Pliva Pharm & Chem Works | Preparation of d-penicillamine and substituted 3-pyrazoline- 5-ones |
| GB1591439A (en) | 1976-10-01 | 1981-06-24 | Glaxo Operations Ltd | 7-syn (oxyimino -acylamido) cephalosporins |
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| US4128425A (en) * | 1977-05-06 | 1978-12-05 | Polaroid Corporation | Photographic developers |
| DD143617A1 (de) | 1979-05-14 | 1980-09-03 | Helmut Dorn | Verfahren zur herstellung von 2-nitro-und 2-amino-5-oxo-perhydro-pyrazolo eckige klammer auf 1,2-a eckige klammer zu pyrazolen |
| DE2931673A1 (de) * | 1979-08-04 | 1981-02-26 | Basf Ag | Pyrazolin-5-on-yl-methyl-(di)thiophosphorsaeureester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen |
| GB2073740A (en) * | 1980-03-03 | 1981-10-21 | Wellcome Found | Pyrazolidinones |
| US4396619A (en) | 1981-09-08 | 1983-08-02 | Eli Lilly And Company | Cephalosporin betaines |
| GB2128984B (en) * | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
| US4465679A (en) * | 1983-01-31 | 1984-08-14 | Usv Pharmaceutical Corporation | 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof |
| AU575854B2 (en) | 1983-10-04 | 1988-08-11 | Shionogi & Co., Ltd. | 7beta-(carboxyalkenamido) cephalosporins |
| HU198186B (en) | 1985-04-30 | 1989-08-28 | Lilly Co Eli | Process for producing pyrazolidinium-ilides |
| IL78629A0 (en) | 1985-04-30 | 1986-08-31 | Lilly Co Eli | 4-substituted diazolidinones |
| DK193086A (da) * | 1985-04-30 | 1987-01-20 | Lilly Co Eli | 7-substituerede bicycliske pyrazolidinoner, fremgangsmaade til fremstilling heraf og mellemprodukter til brug ved fremgangsmaaden |
-
1986
- 1986-04-28 DK DK193086A patent/DK193086A/da not_active Application Discontinuation
- 1986-04-28 HU HU861763A patent/HUT40660A/hu unknown
- 1986-04-28 AU AU56755/86A patent/AU5675586A/en not_active Abandoned
- 1986-04-28 EP EP86303174A patent/EP0202046B1/en not_active Expired - Lifetime
- 1986-04-28 KR KR1019860003251A patent/KR880001092B1/ko not_active IP Right Cessation
- 1986-04-28 IL IL78634A patent/IL78634A0/xx unknown
- 1986-04-28 GR GR861118A patent/GR861118B/el unknown
- 1986-04-28 CA CA000507777A patent/CA1274832A/en not_active Expired - Lifetime
- 1986-04-28 DE DE8686303174T patent/DE3677253D1/de not_active Expired - Lifetime
- 1986-04-28 CN CN198686103619A patent/CN86103619A/zh active Pending
- 1986-04-28 ZA ZA863170A patent/ZA863170B/xx unknown
- 1986-04-28 ES ES554463A patent/ES8801833A1/es not_active Expired
- 1986-04-28 PT PT82468A patent/PT82468B/pt unknown
- 1986-04-28 AT AT86303174T patent/ATE60605T1/de not_active IP Right Cessation
- 1986-04-30 JP JP61100817A patent/JPH0759582B2/ja not_active Expired - Lifetime
- 1986-05-14 US US06/862,913 patent/US4716232A/en not_active Expired - Fee Related
- 1986-05-14 US US06/862,918 patent/US4734504A/en not_active Expired - Lifetime
- 1986-05-14 US US06/862,909 patent/US4734505A/en not_active Expired - Lifetime
- 1986-10-28 JP JP61258084A patent/JPS63112583A/ja active Pending
-
1987
- 1987-10-29 US US07/114,897 patent/US4795815A/en not_active Expired - Lifetime
-
1988
- 1988-04-13 ZA ZA882604A patent/ZA882604B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0202046A1 (en) | 1986-11-20 |
| ZA863170B (en) | 1987-12-30 |
| ES8801833A1 (es) | 1988-02-16 |
| JPH0759582B2 (ja) | 1995-06-28 |
| US4734504A (en) | 1988-03-29 |
| DK193086D0 (da) | 1986-04-28 |
| AU5675586A (en) | 1986-11-13 |
| CA1274832A (en) | 1990-10-02 |
| US4734505A (en) | 1988-03-29 |
| US4716232A (en) | 1987-12-29 |
| IL78634A0 (en) | 1986-08-31 |
| DE3677253D1 (de) | 1991-03-07 |
| CN86103619A (zh) | 1986-10-29 |
| DK193086A (da) | 1987-01-20 |
| HUT40660A (en) | 1987-01-28 |
| PT82468A (en) | 1986-05-01 |
| PT82468B (en) | 1988-03-23 |
| ATE60605T1 (de) | 1991-02-15 |
| ZA882604B (en) | 1989-12-27 |
| JPS61254589A (ja) | 1986-11-12 |
| JPS63112583A (ja) | 1988-05-17 |
| EP0202046B1 (en) | 1991-01-30 |
| GR861118B (en) | 1986-08-18 |
| KR880001092B1 (ko) | 1988-06-23 |
| ES554463A0 (es) | 1988-02-16 |
| US4795815A (en) | 1989-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR860008181A (ko) | 7-치환된 바이시클릭 피라졸리디논의 제조방법 | |
| DE3272792D1 (en) | Process for the preparation of 2-penem compounds | |
| PT87700A (pt) | Process for the preparation of a new pyrazolopyridine compound | |
| FI903879A0 (fi) | Menetelmä valmistaa farmakologisesti käyttökelpoista tiatsoliyhdistettä | |
| ES8304096A1 (es) | "procedimiento para la preparacion de nuevas piriimidinonas". | |
| KR860004032A (ko) | 피페라진 화합물의 제조방법 | |
| DE3167774D1 (en) | 4-substituted-2-oxoazetidine compounds, processes for their preparation, and their use for preparing antibiotics | |
| JPS5543011A (en) | 7-halothiazolylalkoxyiminoacetamido-3-cephem compound | |
| KR910000751A (ko) | 세펨 화합물 및 이의 제조방법 | |
| GB1260882A (en) | New penicillins | |
| DE3270492D1 (en) | Imidazo (4,5-c) pyridines, pharmaceutical compositions containing them and process for their preparation | |
| GB1092921A (en) | Anthranilic acid derivatives | |
| US4060527A (en) | Pyrido[2,3-c]-acridine-1-hydroxy-2-carboxylic acid derivatives | |
| AU5674894A (en) | Azanoradamantanes | |
| GR3002688T3 (en) | Thiadiazolylacetamide derivatives, process for the preparation thereof and their use | |
| ES2010948A6 (es) | Un procedimiento para la preparacion de derivados del acido 3-quinolincarboxilico. | |
| ES2061494T3 (es) | Proceso para la preparacion de derivados de cefalosporina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |